Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BHVN Biohaven Pharmaceutical Holding Co Ltd.

Trading 04-10 13:09:06 EDT

9.13

-0.26

-2.77%

High9.43	Low9.04	Vol431.60K
Open9.26	D1 Closing9.39	Amplitude4.15%
Mkt Cap1.37B	Tradable Cap1.13B	Total Shares150.42M
T/O3.97M	T/O Rate0.35%	Tradable Shares124.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BHVN","market":"US","secType":"STK","nameCN":"Biohaven Pharmaceutical Holding Co Ltd.","latestPrice":9.13,"timestamp":1775840945330,"preClose":9.39,"halted":0,"volume":431597,"delay":0,"changeRate":-0.02768903088391904,"floatShares":124000000,"shares":150417084,"eps":-6.864787,"marketStatus":"Trading","change":-0.26,"latestTime":"04-10 13:09:06 EDT","open":9.26,"high":9.43,"low":9.04,"amount":3966052.300653,"amplitude":0.041534,"askPrice":9.14,"askSize":102,"bidPrice":9.12,"bidSize":277,"shortable":3,"etf":0,"ttmEps":-6.864787,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1775851200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1493870400000,"exchange":"NYSE","adjPreClose":9.39,"preHourTrading":{"tag":"盘前","latestPrice":9.5,"preClose":9.39,"latestTime":"08:41 EDT","volume":1388,"amount":13179.939992000001,"timestamp":1775824864900,"change":0.11,"changeRate":0.011715,"amplitude":0.009585},"postHourTrading":{"tag":"盘后","latestPrice":9.39,"preClose":9.39,"latestTime":"19:43 EDT","volume":100195,"amount":940837.734,"timestamp":1775778231498,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.44812,"impliedVol":0.8101,"impliedVolPercentile":0.06},"requestUrl":"/m/hq/s/BHVN/tweets","defaultTab":"tweets","newsList":[{"id":"2624684261","title":"Why Biohaven (BHVN) Is Up 11.7% After Fully Enrolling Its Phase 2 Obesity Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2624684261","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624684261?lang=en_us&edition=fundamental","pubTime":"2026-04-03 03:26","pubTimestamp":1775157968,"startTime":"0","endTime":"0","summary":"Biohaven announced that it has completed enrollment in a U.S. Phase 2 proof-of-concept trial of taldefgrobep alfa, a myostatin-activin pathway inhibitor being tested as a self-administered obesity treatment, with topline data expected in the second half of 2026.\nAn unusual aspect of taldefgrobep alfa is its prior clinical profile, where participants showed meaningful fat loss alongside gains in lean muscle mass, hinting at a differentiated approach to weight management.\nWith Biohaven’s...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/why-biohaven-bhvn-is-up-117-after-fully-enrolling-its-phase","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/why-biohaven-bhvn-is-up-117-after-fully-enrolling-its-phase","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1093756168.USD","BK4139","BHVN","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624568827","title":"Biohaven Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2624568827","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624568827?lang=en_us&edition=fundamental","pubTime":"2026-04-02 23:41","pubTimestamp":1775144460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BHVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2026 11:41 ET (15:41 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1093756325.SGD","BHVN","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624575278","title":"U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2624575278","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624575278?lang=en_us&edition=fundamental","pubTime":"2026-04-02 15:21","pubTimestamp":1775114493,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United TherapeuticsApril 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nL4N40L0JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBIN","GENK","GD","CSL","BHVN","COP","CVX","GOU","BETA","DK","BOH","GPN","GOOGL","DIN","GOOX","GGLL","BAC","CFG","GE","APLS","DCO","CTRE","AMZN","CAVA","AROC","GOOY","BA","CVI","GOOW","STZ","XOM","BAH","DASX","CW","FBK","GOOP","AZYY","CAG","USAW.SI","DASH","CACI","BJRI","BYND","ALAB","XOMZ","CEG","CQP","BARK","ANRO","LNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621699080","title":"Biohaven Ltd. (BHVN) Gets a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2621699080","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621699080?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:05","pubTimestamp":1774350347,"startTime":"0","endTime":"0","summary":"In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Biohaven Ltd., with a price target of $30.00. Bratzel cov...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/biohaven-ltd-bhvn-gets-a-buy-from-piper-sandler-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/biohaven-ltd-bhvn-gets-a-buy-from-piper-sandler-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU1093756168.USD","LU1093756325.SGD","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620225398","title":"BUZZ-U.S. STOCKS ON THE MOVE-Rivian,  Biohaven, CervoMed","url":"https://stock-news.laohu8.com/highlight/detail?id=2620225398","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620225398?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:15","pubTimestamp":1773926106,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMedWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nL6N4070OP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RIVN","APA","MUD","RVNL","TRGP","RIO.UK","XOMZ","DRI","EMBC","FCXG","BHVN","KBAB","FCX","ALGN","CRVO","ACN","CDE","LIF","MMM","BABU","NWMX","HL","ALBmain","HUMA","MULL","GLSI","JBL","BHP.AU","SCCO","IAUX","89988","SSB","RIO.AU","BBYY","NEM","HBBD.SI","ACIU","BABO","NEMG","GRDN","RVPH"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620228451","title":"BUZZ-Biohaven rises after completing enrollment in mid-stage obesity drug trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2620228451","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620228451?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:42","pubTimestamp":1773924123,"startTime":"0","endTime":"0","summary":"BUZZ-Biohaven rises after completing enrollment in mid-stage obesity drug trial** Shares of drugmaker Biohaven BHVN.N rise 2% to $9.26 premarket** Co says it finished enrolling patients in a mid-stage trial for experimental obesity drug, taldefgrobep alfa, ** Expects trial results in second-half of 2026** Says the injectable drug is being tested as a standalone treatment, given weekly or monthly, on overweight and obese adults** Adds the study will track changes in weight, fat and muscle mass over 24 weeks, followed by a 24-week extension to see if changes to weight and body-composition sustain or improve over a longer period** Earlier studies showed the experimental drug helped reduce fat, while preserving or increasing muscle with side effects similar to placebo** Shares fell ~70% in 2025  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nL4N4071DS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU1093756168.USD","BHVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620475952","title":"BRIEF-Biohaven's Phase 2 Obesity Study With Taldefgrobep Alfa, A Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2620475952","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620475952?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:57","pubTimestamp":1773921427,"startTime":"0","endTime":"0","summary":"BRIEF-Biohaven's Phase 2 Obesity Study With Taldefgrobep Alfa, A Novel Myostatin-Activin Pathway Inhibitor, Completes EnrollmentMarch 19 (Reuters) - Biohaven Ltd BHVN.N:BIOHAVEN'S PHASE 2 OBESITY STUD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nFWN4070D8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU1093756168.USD","BHVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620224241","title":"Biohaven completes enrollment in Phase 2 study on taldefgrobep alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=2620224241","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620224241?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:35","pubTimestamp":1773920113,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) announced the completion of enrollment in a Phase 2 proof-of-concept study with its myostatin-activin pathway inhibitor, taldefgrob...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biohaven-completes-enrollment-in-phase-2-study-on-taldefgrobep-alfa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biohaven-completes-enrollment-in-phase-2-study-on-taldefgrobep-alfa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756168.USD","BK4139","BHVN","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620425422","title":"Biohaven completes enrollment in Phase 2 obesity trial of taldefgrobep alfa, with topline data due in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620425422","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620425422?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:30","pubTimestamp":1773919844,"startTime":"0","endTime":"0","summary":"Biohaven reported completion of enrollment in a Phase 2 randomized, double-blind, placebo-controlled, dose-ranging study of taldefgrobep alfa as monotherapy in adults with overweight or obesity.The trial is evaluating once-weekly and once-monthly dosing delivered by a self-administered autoinjector.The double-blind treatment period lasts 24 weeks, with a 24-week open-label extension.The primary endpoint is percent change in total body weight from baseline to Week 24, with secondary endpoints including percent change in total body fat mass and lean mass.Results have not been presented; topline data are expected in 2H 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL2krBTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU1093756168.USD","BHVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620201449","title":"U.S. RESEARCH ROUNDUP- Biogen, Eli Lilly, Johnson & Johnson","url":"https://stock-news.laohu8.com/highlight/detail?id=2620201449","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620201449?lang=en_us&edition=fundamental","pubTime":"2026-03-17 15:31","pubTimestamp":1773732703,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Biogen, Eli Lilly, Johnson & JohnsonMarch 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Biog","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL4N4050LR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XOMO","FANG","ATLX","COP","ELIS","LU1815333072.USD","STZ","ALGN","LBRT","EXR","IE0002270589.USD","LLII","LLY","CF","XOMZ","CVX","EQT","DVN","CNMD","CRC","DOV","CVLT","EOG","CTMX","EWTX","DLTR","APD","KNTK","LLYZ","MTDR","BMY","EPD","JNJ","CTRA","LLYX","EGP","XOM","CRGY","GPOR","MPC","BHVN","CYTK","FIVE","DFLI","ICHR","INGR","BK4139","XOMX","BIIB","ELIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619148719","title":"Biohaven Ltd. Announces Annual Shareholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2619148719","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619148719?lang=en_us&edition=fundamental","pubTime":"2026-03-14 04:56","pubTimestamp":1773435368,"startTime":"0","endTime":"0","summary":"Biohaven will hold its annual meeting on April 28, 2026 in Virgin Gorda, British Virgin Islands. Shareholders will vote on the election of three director nominees: Michael Heffernan, Irina Antonijevic, and Robert Hugin. The meeting will also include a vote to ratify Ernst & Young as Biohaven’s independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, shareholders will vote on an advisory proposal regarding compensation for Biohaven’s named executive officers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDLtHfrS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU1093756168.USD","BHVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618919535","title":"Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Biohaven Ltd. (BHVN) and Siemens Healthineers AG (OtherSEMHF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618919535","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618919535?lang=en_us&edition=fundamental","pubTime":"2026-03-11 15:20","pubTimestamp":1773213645,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX – Research Report),...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-praxis-precision-medicines-prax-biohaven-ltd-bhvn-and-siemens-healthineers-ag-othersemhf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-praxis-precision-medicines-prax-biohaven-ltd-bhvn-and-siemens-healthineers-ag-othersemhf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BHVN","IE00BJT1NW94.SGD","BK4585","LU0128526141.USD","BK4139","LU1093756168.USD","HCSG","IE00B2B36J28.USD","LABU","IE00B4R5TH58.HKD","LU1093756325.SGD","IE00BJJMRZ35.SGD","BK4581","IE0002141913.USD","IE0009355771.USD","BK4210","IE00BFTCPJ56.SGD","AG","LU0320765992.SGD","BK4588","BK4137","XBI","PRAX","LU0029874061.USD","LU0109394709.USD","LU0889565916.HKD","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165103273","title":"Stock Track | Biohaven Pharmaceutical Soars 5.14% Intraday on Positive Competitor Drug Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1165103273","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165103273?lang=en_us&edition=fundamental","pubTime":"2026-03-10 03:34","pubTimestamp":1773084889,"startTime":"0","endTime":"0","summary":"Biohaven Pharmaceutical Holding Co Ltd. (BHVN) experienced a significant intraday surge of 5.14% on Monday.The sharp rise is attributed to positive clinical trial data released by competitor Xenon...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618765716","title":"Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618765716","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618765716?lang=en_us&edition=fundamental","pubTime":"2026-03-10 01:50","pubTimestamp":1773078626,"startTime":"0","endTime":"0","summary":"Raymond James keeps a Strong Buy rating on Biohaven (BHVN) shares following competitor Xenon Pharmaceuticals’ (XENE) top-line Phase 3 readout for K...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/raymond-james-says-rival-readout-gives-biohavens-opakalim-room-to-differentiate-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/raymond-james-says-rival-readout-gives-biohavens-opakalim-room-to-differentiate-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU1363072403.SGD","LU1093756168.USD","BK4588","IE00B3QW5Z07.USD","BK4585","RJF","IE00BGHQF748.EUR","BHVN","LU2265009873.SGD","IE00B64PRP62.GBP","LU0971096721.USD","LU1093756325.SGD","LU1804176565.USD","XENE","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618783146","title":"Biohaven fractionally lower after Xenon reports azetukalner Phase 3 hit target","url":"https://stock-news.laohu8.com/highlight/detail?id=2618783146","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618783146?lang=en_us&edition=fundamental","pubTime":"2026-03-09 23:55","pubTimestamp":1773071709,"startTime":"0","endTime":"0","summary":"Shares of Biohaven (BHVN) were sharply higher in early trading, but have given up their gains and moved into negative territory during Monday morni...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biohaven-fractionally-lower-after-xenon-reports-azetukalner-phase-3-hit-target-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biohaven-fractionally-lower-after-xenon-reports-azetukalner-phase-3-hit-target-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU1093756168.USD","LU1093756325.SGD","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618678855","title":"What's Going On With Biohaven Stock On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618678855","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618678855?lang=en_us&edition=fundamental","pubTime":"2026-03-09 23:47","pubTimestamp":1773071220,"startTime":"0","endTime":"0","summary":"Biohaven shares rose in premarket trading after Xenon's Phase 3 epilepsy study showed strong seizure reduction results.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/09/Richmond--Virginia--Usa---9-May-2019-Ill.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/09/Richmond--Virginia--Usa---9-May-2019-Ill.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51133485/whats-going-on-with-biohaven-stock-on-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51133485/whats-going-on-with-biohaven-stock-on-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0266512127.USD","BK4217","LU0300736492.USD","SMA","LU0300736062.USD","BHVN","LU1093756325.SGD","BK4585","BK4139","XENE","MPC","LU0368265418.SGD","LU0788109394.HKD","LU0456854461.SGD","LU0266512473.USD","LU0122376428.USD","LU1093756168.USD","IE00BSNM7G36.USD","BK4588","BK4138","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112851597","title":"Stock Track | Biohaven Pharmaceutical Plummets 6.45% Intraday Amid Conflicting Analyst Ratings","url":"https://stock-news.laohu8.com/highlight/detail?id=1112851597","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112851597?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:44","pubTimestamp":1773063884,"startTime":"0","endTime":"0","summary":"Biohaven Pharmaceutical Holding Co Ltd. (BHVN) saw its shares plummet 6.45% during intraday trading on Monday, marking a significant decline for the healthcare stock.The sharp drop follows the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618113086","title":"Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (BHVN) and Atai Beckley N.V. (ATAI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618113086","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618113086?lang=en_us&edition=fundamental","pubTime":"2026-03-09 11:40","pubTimestamp":1773027620,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biohaven Ltd. (BHVN – Research Report) and Atai Beckley N.V. (ATA...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-biohaven-ltd-bhvn-and-atai-beckley-n-v-atai-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-biohaven-ltd-bhvn-and-atai-beckley-n-v-atai-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4581","XLV","LU0128526141.USD","BK4137","BHVN","HCSG","LU0029874061.USD","BK4007","LABU","BK4539","ATAI","BK4139","LU1093756325.SGD","LU1093756168.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616537331","title":"Biohaven Is Maintained at Neutral by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2616537331","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616537331?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:08","pubTimestamp":1772626080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BHVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2026 07:08 ET (12:08 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU1093756168.USD","BK4139","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129379880","title":"Stock Track | Biohaven Pharmaceutical Plummets 7.45% Intraday After BofA Lowers Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1129379880","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129379880?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:57","pubTimestamp":1772549878,"startTime":"0","endTime":"0","summary":"Biohaven Pharmaceutical Holding Co Ltd. (BHVN) stock plummeted 7.45% during intraday trading on Tuesday, reflecting significant negative investor sentiment.The sharp decline followed analyst actions...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BHVN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biohaven.com","stockEarnings":[{"period":"1week","weight":-0.0418},{"period":"1month","weight":-0.0857},{"period":"3month","weight":-0.1548},{"period":"6month","weight":-0.4057},{"period":"1year","weight":-0.4971},{"period":"ytd","weight":-0.1683}],"compareEarnings":[{"period":"1week","weight":0.0367},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0204},{"period":"6month","weight":0.0412},{"period":"1year","weight":0.2393},{"period":"ytd","weight":-0.0029}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.071849},{"month":2,"riseRate":0.222222,"avgChangeRate":-0.026101},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.120539},{"month":4,"riseRate":0.555556,"avgChangeRate":0.025192},{"month":5,"riseRate":0.625,"avgChangeRate":0.144142},{"month":6,"riseRate":0.555556,"avgChangeRate":0.056007},{"month":7,"riseRate":0.555556,"avgChangeRate":0.010799},{"month":8,"riseRate":0.666667,"avgChangeRate":0.043364},{"month":9,"riseRate":0.777778,"avgChangeRate":0.09598},{"month":10,"riseRate":0.555556,"avgChangeRate":-0.072057},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.042561},{"month":12,"riseRate":0.555556,"avgChangeRate":0.054983}],"exchange":"NYSE","name":"Biohaven Pharmaceutical Holding Co Ltd.","nameEN":"Biohaven Pharmaceutical Holding Co Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biohaven Pharmaceutical Holding Co Ltd.(BHVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biohaven Pharmaceutical Holding Co Ltd.,BHVN,Biohaven Pharmaceutical Holding Co Ltd.股票,Biohaven Pharmaceutical Holding Co Ltd.股票老虎,Biohaven Pharmaceutical Holding Co Ltd.股票老虎国际,Biohaven Pharmaceutical Holding Co Ltd.行情,Biohaven Pharmaceutical Holding Co Ltd.股票行情,Biohaven Pharmaceutical Holding Co Ltd.股价,Biohaven Pharmaceutical Holding Co Ltd.股市,Biohaven Pharmaceutical Holding Co Ltd.股票价格,Biohaven Pharmaceutical Holding Co Ltd.股票交易,Biohaven Pharmaceutical Holding Co Ltd.股票购买,Biohaven Pharmaceutical Holding Co Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biohaven Pharmaceutical Holding Co Ltd.(BHVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction